Effects of GH on Body Composition and Cardiovascular Risk Markers in Young Men With Abdominal Obesity
Open Access
- 1 September 2013
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 98 (9) , 3864-3872
Abstract
Context: Visceral adiposity is associated with increased cardiometabolic risk and decreased GH secretion. Objective: Our objective was to determine the effects of GH administration in abdominally obese young men on body composition, including liver fat, mitochondrial function, and cardiovascular (CV) risk markers. Design and Participants: This was a 6-month, randomized, double-blind, placebo-controlled study with 62 abdominally obese men (IGF-1 below the mean, no exclusion based on GH level), 21 to 45 years of age. Main Outcome Measures: We evaluated abdominal fat depots, thigh muscle and fat (computed tomography), fat and lean mass (dual-energy x-ray absorptiometry), intramyocellular and intrahepatic lipids (proton magnetic resonance spectroscopy), mitochondrial function (dynamic phosphorous magnetic resonance spectroscopy), CV risk markers, carotid intimal-medial thickness, and endothelial function. Results: GH administration resulted in a mean IGF-1 SD score increase from −1.9 ± 0.08 to −0.2 ± 0.3 in the GH group and a decrease in visceral adipose tissue (VAT), VAT/sc adipose tissue, trunk/extremity fat, intrahepatic lipids, high-sensitivity C-reactive protein and apolipoprotein B/low-density lipoprotein vs placebo after controlling for the increase in weight observed in both groups. There were inverse associations between change in IGF-1 levels and change in VAT, VAT/sc adipose tissue, trunk fat, trunk/extremity fat, high-sensitivity C-reactive protein, and apolipoprotein B. Mitochondrial function improved in the GH group compared with placebo after controlling for change in glucose. There was no change in thigh fat, muscle mass, intramyocellular lipids, cholesterol, fibrinogen, intimal-medial thickness, or endothelial function. There was no increase in fasting glucose or hemoglobin A1c in the GH vs placebo group, although glucose during the 2-hour oral glucose tolerance test increased slightly. Conclusion: GH replacement in abdominally obese men improves body composition, including liver fat, mitochondrial function, and markers of CV risk. Although fasting glucose was unchanged, a slight increase in 2-hour glucose during an oral glucose tolerance test was noted.Keywords
This publication has 41 references indexed in Scilit:
- Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trialEuropean Journal of Endocrinology, 2012
- Modular MR-compatible lower leg exercise device for whole-body scannersSkeletal Radiology, 2011
- Mitochondrial Function and Insulin Resistance in Overweight and Normal-Weight ChildrenThe Journal of Clinical Endocrinology & Metabolism, 2009
- Peak Growth Hormone-Releasing Hormone-Arginine-Stimulated Growth Hormone Is Inversely Associated with Intramyocellular and Intrahepatic Lipid Content in Premenopausal Women with ObesityThe Journal of Clinical Endocrinology & Metabolism, 2009
- Growth Hormone Deficiency by Growth Hormone Releasing Hormone-Arginine Testing Criteria Predicts Increased Cardiovascular Risk Markers in Normal Young Overweight and Obese WomenThe Journal of Clinical Endocrinology & Metabolism, 2008
- Inflammation is associated with a decrease of lipogenic factors in omental fat in womenAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2008
- Growth Hormone Decreases Visceral Fat and Improves Cardiovascular Risk Markers in Women with Hypopituitarism: A Randomized, Placebo-Controlled StudyThe Journal of Clinical Endocrinology & Metabolism, 2008
- Enhancement of Muscle Mitochondrial Function by Growth HormoneThe Journal of Clinical Endocrinology & Metabolism, 2008
- Impaired Mitochondrial Activity in the Insulin-Resistant Offspring of Patients with Type 2 DiabetesNew England Journal of Medicine, 2004
- Relaxation times of 31P‐metabolites in human calf muscle at 3 TMagnetic Resonance in Medicine, 2003